Startup that specializes in the development and commercialization of long-acting treatments through bioerodible drug delivery implants gets featured in FirstWorld: FutureViews: Injectables and Implantables report
(June 2020) – This FirstWorld report details the many opportunities present for the future of injectables and implantables, while also uncovering challenges that may be faced when pursuing the field. In order to gain these insights three experts in the field, René Holm, Idicula Mathew, and Christopher Rhodes, were screened and chosen to be interviewed. René Holm, the Head and Scientific Director of Drug Product Development – Liquids and Parenterals at The Janssen Pharmaceutical Companies of Johnson & Johnson, offered his expertise due to his large presence in pharmaceutical and biotechnology research. Idicula Mathew, CEO and co-founder of Hera Health Solutions, was selected due to his experience in designing and developing long-acting treatments through biodegradable drug eluting implants. Christopher Rhodes, President, CEO, and Founder of Drug Delivery Experts, provided his 25+ years of knowledge in pharmaceutical, biotechnology, and medical device companies. Together, these three individuals made way for an abundance of insights to be included in the report.
It is evident that there is a strong place for injectables and implantables in the medical device market as discussed in the article. Not only are they more efficient, but these types of drug delivery systems are more patient friendly. A big issue facing pharma is patient compliance. Without patient compliance there is little to no treatment adherence, which results in worse patient outcomes.
“For our team at Hera Health Solutions, we believe that clinical applications of long-acting injectables and implants will have a huge impact on patient outcomes. Unfortunately, compliance and usability are two of the biggest issues preventing good patient outcomes. Take our bio-erodible contraceptive arm implant as an example. While following a strict daily pill-taking regimen can be very effective, it can be virtually useless if not administered properly and timely” says Idicula Mathew, Co-Founder & CEO, Hera Health Solutions, US.
To read more about patient and physician views, regulatory challenges, and emerging market opportunities for injectables and implantables read the full report here: